|
| Status |
Public on May 21, 2015 |
| Title |
33D9_Untreated_786-O |
| Sample type |
RNA |
| |
|
| Source name |
Frozen 786-O Xenograft Tumors
|
| Organism |
Homo sapiens |
| Characteristics |
treatment: Frozen 786-O Untreated Sorafenib
host organism: Mus musculus
cell type: renal cell carcinoma
cell line: 786-O
|
| Treatment protocol |
biopsy specimens were snap frozen at time of mouse surgery, then stored at -80C until time of total RNA extraction
|
| Growth protocol |
Female athymic nude/beige mice (Charles River Laboratories, MA) were used for subcutaneous xenograft tumor models. All experiments were approved by the Beth Israel Deaconess Medical Center Institutional Animal Care and Use Committee. To establish RCC tumor xenografts, 1 x 10^7 786-O or A498 tumor cells were prepared and injected subcutaneously into the flanks of 6-8 week old mice. To ensure a consistent size at the outset of treatment, tumors were measured with calipers daily once they reached a diameter of 3-5 mm. Sunitinib (additive-free, 53.6 mg/kg) was administered 6 out of 7 days per week by gavage beginning when the tumors had grown to a diameter of 12 mm. Sorafenib (80 mg/kg, Bayer) was administered 6 out of 7 days per week by gavage beginning when the tumors had grown to a diameter of 12 mm. Treated and control tumors were again measured daily during therapy.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Trizol extraction was performed after tumor were excised and frozen
|
| Label |
biotin
|
| Label protocol |
Standard Affymetrix Protocol
|
| |
|
| Hybridization protocol |
The hybridization and subsequent washing and staining were performed on the Affymetrix GeneChip® Array Station (GCAS) automation platform.
|
| Scan protocol |
The arrays were scanned on the GeneChip® HT Array Plate Scanner (Affymetrix 00-0332).
|
| Description |
Frozen 786-O Untreated
|
| Data processing |
The data was normalised using Robust Multichip Average (RMA), Dchip and MAS5 algorithms
|
| |
|
| Submission date |
Dec 10, 2014 |
| Last update date |
May 21, 2015 |
| Contact name |
Manoj Bhasin |
| Phone |
6176670009
|
| Organization name |
Beth Israel Deaconess Medical Center
|
| Street address |
330 Brookline Avenue RN 380E
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02115 |
| Country |
USA |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE64052 |
Gene expression changes during resistance toward vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy in renal cell carcinoma (RCC) |
|
